<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053430</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AI047742-01A1</org_study_id>
    <secondary_id>7R01AI047742-02</secondary_id>
    <nct_id>NCT00053430</nct_id>
  </id_info>
  <brief_title>Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People</brief_title>
  <official_title>Pharmacologic T Cell Costimulation In HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Despite treatment with anti-HIV drugs, people infected with HIV continue to have problems
      with their immune systems. This study will evaluate whether the drug thalidomide, which
      stimulates the immune system's T cells, can improve immune system function in people with
      HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with chronic HIV infection, HIV replication and abnormalities in immune function
      persist following treatment with highly active antiretroviral therapy (HAART). Specifically,
      costimulatory T cell interactions are impaired. The immune modulatory drug thalidomide was
      recently found to costimulate T cells. Pharmacologic T cell costimulation may compensate for
      the T cell deficiencies in people with HIV disease and improve immune function. This study
      will test whether thalidomide treatment enhances HIV and cytomegalovirus (CMV)-specific
      immunity in patients with HIV and CMV, and will evaluate the effect of thalidomide on HIV
      replication.

      In this study, 40 HIV and CMV infected patients on HAART and 40 HIV uninfected CMV
      seropositive controls will be randomly assigned to low dose thalidomide or placebo treatment
      for 28 days. T cell responses and HIV replication and genetic diversification will be
      assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Doubling in HIV Pol-specific CD8 cells, measured by ELISPOT</measure>
    <time_frame>Through Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in CMV pp65 CD8 cells, measured by ELISPOT in the thalidomide treatment group</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in HIV p24-specific IFN-gamma-secreting CD4 cells in the thalidomide treatment group, measured by fluorescence-activated cell sorting (FACS)</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in cytomegalovirus (CMV)-specific interferon (IFN)-gamma-secreting CD4 T cells in the thalidomide treatment group, measured by FACS</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in the frequency of keyhole limpet hemocyanin (KLH)-specific lymphocyte proliferative responses in the thalidomide treatment group</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in adverse events in the thalidomide treatment group</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive low dose thalidomide for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive low dose thalidomide placebo for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Tablet taken orally daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide placebo</intervention_name>
    <description>Placebo tablet taken orally daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  HIV-infected for at least 5 years prior to study entry

          -  CD4 count of 300/mm3 or above

          -  Pre-HAART nadir CD4 count of 300/mm3 or less

          -  CMV infection

          -  HAART for 12 months prior to study entry

          -  Same effective HAART regimen for 3 months prior to study entry

          -  HIV viral load less than 200 copies/ml

          -  Clinically stable

        Exclusion Criteria

          -  Active opportunistic infection

          -  Females of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Haslett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Microbiology and Immunology, University of Miami School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis. 2003 Mar 15;187(6):946-55. Epub 2003 Mar 6.</citation>
    <PMID>12660941</PMID>
  </reference>
  <reference>
    <citation>Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneekarn N, Vongchan P, Corral LG, Elbeik T, Shen Z, Kaplan G. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1169-79.</citation>
    <PMID>10480630</PMID>
  </reference>
  <reference>
    <citation>Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003 Feb;25(2):342-95. Review.</citation>
    <PMID>12749503</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2003</study_first_submitted>
  <study_first_submitted_qc>January 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2003</study_first_posted>
  <last_update_submitted>August 6, 2009</last_update_submitted>
  <last_update_submitted_qc>August 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rona Siskind</name_title>
    <organization>DAIDS</organization>
  </responsible_party>
  <keyword>Immune Modulation</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

